See the article in full here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"This article appeared in Fierce Biotech, March 2 2022 See the article in full here<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[8],"tags":[],"acf":[],"yoast_head":"\n
Novartis backs Epsilogen's bid to turn 'Cinderella antibody' into new class of cancer drug | Fierce Biotech - Epsilogen<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis backs Epsilogen's bid to turn 'Cinderella antibody' into new class of cancer drug | Fierce Biotech - Epsilogen\" \/>\n<meta property=\"og:description\" content=\"This article appeared in Fierce Biotech, March 2 2022 See the article in full here\" \/>\n<meta property=\"og:url\" content=\"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/\" \/>\n<meta property=\"og:site_name\" content=\"Epsilogen\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-02T14:03:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-12T09:51:57+00:00\" \/>\n<meta name=\"author\" content=\"Daniel\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Daniel\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/\"},\"author\":{\"name\":\"Daniel\",\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/person\/25beed45dd34b674c4e479b4132fa3a0\"},\"headline\":\"Novartis backs Epsilogen’s bid to turn ‘Cinderella antibody’ into new class of cancer drug | Fierce Biotech\",\"datePublished\":\"2022-03-02T14:03:55+00:00\",\"dateModified\":\"2024-03-12T09:51:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/\"},\"wordCount\":30,\"publisher\":{\"@id\":\"https:\/\/epsilogen.com\/#organization\"},\"articleSection\":[\"In the News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/\",\"url\":\"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/\",\"name\":\"Novartis backs Epsilogen's bid to turn 'Cinderella antibody' into new class of cancer drug | Fierce Biotech - Epsilogen\",\"isPartOf\":{\"@id\":\"https:\/\/epsilogen.com\/#website\"},\"datePublished\":\"2022-03-02T14:03:55+00:00\",\"dateModified\":\"2024-03-12T09:51:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/epsilogen.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis backs Epsilogen’s bid to turn ‘Cinderella antibody’ into new class of cancer drug | Fierce Biotech\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/epsilogen.com\/#website\",\"url\":\"https:\/\/epsilogen.com\/\",\"name\":\"Epsilogen\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/epsilogen.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/epsilogen.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/epsilogen.com\/#organization\",\"name\":\"Epsilogen\",\"url\":\"https:\/\/epsilogen.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg\",\"contentUrl\":\"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg\",\"width\":267,\"height\":64,\"caption\":\"Epsilogen\"},\"image\":{\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/person\/25beed45dd34b674c4e479b4132fa3a0\",\"name\":\"Daniel\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/338bc7609426d1862789601c4efdafb0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/338bc7609426d1862789601c4efdafb0?s=96&d=mm&r=g\",\"caption\":\"Daniel\"},\"sameAs\":[\"https:\/\/epsilogen.com\"],\"url\":\"https:\/\/epsilogen.com\/author\/daniel\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novartis backs Epsilogen's bid to turn 'Cinderella antibody' into new class of cancer drug | Fierce Biotech - Epsilogen","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/","og_locale":"en_US","og_type":"article","og_title":"Novartis backs Epsilogen's bid to turn 'Cinderella antibody' into new class of cancer drug | Fierce Biotech - Epsilogen","og_description":"This article appeared in Fierce Biotech, March 2 2022 See the article in full here","og_url":"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/","og_site_name":"Epsilogen","article_published_time":"2022-03-02T14:03:55+00:00","article_modified_time":"2024-03-12T09:51:57+00:00","author":"Daniel","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Daniel","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/#article","isPartOf":{"@id":"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/"},"author":{"name":"Daniel","@id":"https:\/\/epsilogen.com\/#\/schema\/person\/25beed45dd34b674c4e479b4132fa3a0"},"headline":"Novartis backs Epsilogen’s bid to turn ‘Cinderella antibody’ into new class of cancer drug | Fierce Biotech","datePublished":"2022-03-02T14:03:55+00:00","dateModified":"2024-03-12T09:51:57+00:00","mainEntityOfPage":{"@id":"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/"},"wordCount":30,"publisher":{"@id":"https:\/\/epsilogen.com\/#organization"},"articleSection":["In the News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/","url":"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/","name":"Novartis backs Epsilogen's bid to turn 'Cinderella antibody' into new class of cancer drug | Fierce Biotech - Epsilogen","isPartOf":{"@id":"https:\/\/epsilogen.com\/#website"},"datePublished":"2022-03-02T14:03:55+00:00","dateModified":"2024-03-12T09:51:57+00:00","breadcrumb":{"@id":"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/epsilogen.com\/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/epsilogen.com\/"},{"@type":"ListItem","position":2,"name":"Novartis backs Epsilogen’s bid to turn ‘Cinderella antibody’ into new class of cancer drug | Fierce Biotech"}]},{"@type":"WebSite","@id":"https:\/\/epsilogen.com\/#website","url":"https:\/\/epsilogen.com\/","name":"Epsilogen","description":"","publisher":{"@id":"https:\/\/epsilogen.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/epsilogen.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/epsilogen.com\/#organization","name":"Epsilogen","url":"https:\/\/epsilogen.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/","url":"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg","contentUrl":"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg","width":267,"height":64,"caption":"Epsilogen"},"image":{"@id":"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/epsilogen.com\/#\/schema\/person\/25beed45dd34b674c4e479b4132fa3a0","name":"Daniel","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/epsilogen.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/338bc7609426d1862789601c4efdafb0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/338bc7609426d1862789601c4efdafb0?s=96&d=mm&r=g","caption":"Daniel"},"sameAs":["https:\/\/epsilogen.com"],"url":"https:\/\/epsilogen.com\/author\/daniel\/"}]}},"_links":{"self":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/posts\/1518"}],"collection":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/comments?post=1518"}],"version-history":[{"count":1,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/posts\/1518\/revisions"}],"predecessor-version":[{"id":2074,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/posts\/1518\/revisions\/2074"}],"wp:attachment":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/media?parent=1518"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/categories?post=1518"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/tags?post=1518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}